Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Clinical Study To Evaluate the Sensitivity of Circulating Iset® by Rarecells Molecular Biomarkers for Early Detection of Lung Cancer
Rarecells Diagnostics SAS
50 participants
Nov 13, 2024
OBSERVATIONAL
Conditions
Summary
Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management. This study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.
Eligibility
Inclusion Criteria8
- Male or female aged between 35 and 85 years
- Patient diagnosed with resectable lung cancer (by imaging and/or pathological examination) not yet treated for this cancer.
- Patient capable of giving free, informed, and express consent
- The assessment of successful elected surgery implies, but is not limited to, the following:
- Exclusion of detectable extra thoracic and distant metastases
- Determination of the presence or absence of superior mediastinal lymph node metastases
- Definition of the histologic or cell type, whenever possible
- Evaluation of operative risk
Exclusion Criteria4
- Patient diagnosed and/or treated previously for lung cancer or another cancer, regardless of duration
- Patient treated with neoadjuvant treatment
- Pregnant women
- Patient presenting psychiatric or neurological disorders preventing them from understanding the research
Interventions
ctDNA for the analysis of lung cancer mutations in patients with operable tumors.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06546007